Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)

by Utkarsh H. Acharya, Roland B. Walter
Published 2020-12-01

Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization.

by Eva Jager, Vincent H J van der Velden, Jeroen G te Marvelde, Roland B Walter, Zvia Agur, Vladimir Vainstein
Published 2011-01-01

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.

by Kimberly H Harrington, Chelsea J Gudgeon, George S Laszlo, Kathryn J Newhall, Angus M Sinclair, Stanley R Frankel, Roman Kischel, Guang Chen, Roland B Walter
Published 2015-01-01

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

by David B Rosen, Kimberly H Harrington, James A Cordeiro, Ling Y Leung, Santosh Putta, Norman Lacayo, George S Laszlo, Chelsea J Gudgeon, Donna E Hogge, Rachael E Hawtin, Alessandra Cesano, Roland B Walter
Published 2013-01-01

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the C...

by George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Alex Kentsis, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Roland B. Walter
Published 2016-11-01

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Trans...

by Linde M. Morsink, Brenda M. Sandmaier, Megan Othus, Raffaele Palmieri, Noa Granot, Evandro D. Bezerra, Brent L. Wood, Marco Mielcarek, Gary Schoch, Chris Davis, Mary E. D. Flowers, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter
Published 2020-08-01